National Institute of Pathology Victor Babeş – Bucharest

What National Institute of Pathology Victor Babeş – Bucharest does

National Institute of Pathology Victor Babeş (IVB) is a Romanian public research institute founded in 1887 and operating under the Romanian Ministry of Research, Innovation and Digitalisation. It specializes in pathology and biomedical sciences with research programs spanning redox biology, radiobiology, astrobiology, cancer research, neurodegenerative disease, and photodynamic therapy development. The institute operates specialized laboratories including the Radiobiology Laboratory led by Elena Milanesi, a Diagnostic Centre providing pathology services to patients, and multiple research units conducting genomics, proteomics, metabolomics, and biomarker discovery. Core technical platforms include NRF2 transcription factor research covering over 250 stress response genes, ELI-NP radiation research using multi-component ionizing radiation and FLASH radiotherapy, electron microscopy for ultrastructural pathology, and porphyrin-based theranostic compound development supported by over 50 patents.

The institute's business model rests on four revenue streams: Romanian government research funding through national programs such as Program Nucleu (2023-2026) and EXCELSAN (31PFE/30.12.2021); EU and international research grants including ROGEN (2024-2029), CANTAVAC, PNRR, ELI-RO, and ESA's AO-2017-IBER program; diagnostic services billed through the Romanian public healthcare system at the Diagnostic Centre; and modest conference and workshop registration fees (100-500 RON per participant). Go-to-market occurs through institutional channels rather than commercial sales, with marketing driven by the Annual Pathology Conference, peer-reviewed scientific publications, visiting professor lectureships, and project collaborations with domestic and international partners including IFIN-HH, University of Bucharest, ICGEB Trieste, GSI Germany, Autonomous University of Madrid, and EU-ROS/BenBedPhar COST Actions.

IVB holds JCI accreditation and serves Romanian healthcare providers, academic and research institutions, pharmaceutical/biotechnology companies for preclinical research, and medical professionals seeking continuing education. The institute employs 51-100 staff, has published hundreds of papers in high-impact journals (impact factors up to 17.013), and operates under a published 2025-2029 Strategic Development Plan. Headquartered at Splaiul Independenţei 99-101, Sector 5, Bucharest, IVB functions as a non-commercial public research entity rather than a product company.

Name

National Institute of Pathology Victor Babeş – Bucharest

Legal name

Institutul Național de Cercetare-Dezvoltare în Domeniul Patologiei și Științelor Biomedicale Victor Babeș București

Website

https://ivb.ro

Company type

Private

Founded year

1887

Operating status

Operating

Headcount range

11–50 employees

Short description

Romanian public research institute founded in 1887 specializing in pathology and biomedical sciences, conducting research in redox biology, radiobiology, cancer therapeutics, and neurodegenerative diseases while providing diagnostic services and training to the Romanian healthcare system.

Ownership category

akta.pro rank

Product category

Pathology and Biomedical Research Services

NAICS

Medical and Diagnostic Laboratories (62151), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industry

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

Keywords

• Pathology research
• Biomedical research
• Diagnostic services
• Radiobiology research
• Photodynamic therapy

Headquarters

HQ city

Bucurestii Noi

HQ country

Romania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Government Research Funding: Core funding from Romanian Ministry of Research, Innovation and Digitalisation through national research programs including Program Nucleu and institutional excellence projects like EXCELSAN.
2. Diagnostic Services: Diagnostic centre providing pathology services to patients. Operating hours Monday-Friday 09:00-16:00.
3. EU Research Grants: Funding from European programs including ROGEN (genome research), CANTAVAC (vaccine development), PNRR, ELI-RO, and various international collaborations.
4. Conference and Education Fees: Registration fees for Annual Pathology Conference and educational workshops (200-500 RON per participant).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The National Institute of Pathology Victor Babeş operates as a Romanian national research-and-development institute providing medical pathology diagnostic services through its Diagnostic Centre, conducting biomedical and pathology research via specialized laboratories (Radiobiology Laboratory, Diagnostic Centre, multiple research units), and delivering professional education through workshops, scientific publication training, and the Annual Pathology Conference. Core research areas include redox biology, radiobiology, astrobiology, cancer theranostics, neurodegenerative disease research, and photodynamic therapy development.

Product overview

The National Institute of Pathology Victor Babeş – Bucharest (INCD „Victor Babeș”) is a Romanian research institute specializing in biomedical research and diagnostics. The institute operates as a unified service organization offering five interconnected offerings: a Diagnostic Center providing medical pathology services; a Radiobiology Laboratory conducting research on redox biology, radiobiology, and astrobiology; Biomedical Research Services covering genomics, proteomics, and biomarker discovery; Education and Training Programs including workshops and youth research initiatives; and hosting the Annual Pathology Conference. The institute functions primarily as a public research institution rather than a commercial product company.

Differentiator

Problem solved

Functional benefit

Brands

• Diagnostic Centre: Patient diagnostic services operating Monday-Friday 09:00-16:00

Products and services

• Diagnostic Centre Services Medical diagnostic laboratory offering pathology testing and analysis for patients, operating Monday-Friday 09:00-16:00 at the institute's Bucharest headquarters with a dedicated patient contact line (021 319 27 34). JCI-accredited.
• Radiobiology Laboratory Research Services Research services investigating redox changes in health and disease, with emphasis on radiobiology and astrobiology, including space radiation studies and FLASH radiotherapy research in collaboration with ELI-NP.
• Biomedical Research Services Research and development services in biomedical sciences including genomics, proteomics, metabolomics, molecular pathology, and biomarker discovery for cancer and other diseases.
• Education and Training Programs Academic education services including the 'School from Vacation' youth program, workshops on electron microscopy sample preparation, scientific publication strategies, and professional training for medical researchers.
• Annual Pathology Conference Annual pathology symposium held in Bucharest, bringing together researchers, clinicians and industry; CME-accredited by the Romanian College of Physicians with conference abstracts indexed in Biomedical Papers – Olomouc (PubMed, WoS, Scopus).

Quantifiable outcome

• Over 50 patents held including porphyrin derivatives for theranostics, magnetic nanostructures for cancer diagnostics, and various therapeutic compounds
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• ROGEN Consortium (Development of genome-based research in Romania)coreStrategic or Co-development Partner · 1 January 2024Multi-institutional consortium led by the institute for developing genome-based research in Romania. Contract 96006/17.12.2024, running 2024-2029. Focus on genetic research infrastructure and capabilities development across Romanian research institutions.
• Biotehnos SAminorStrategic or Co-development Partner · 1 January 2022SME partner in PORPHYDERM project for developing topical photodynamic therapy formulations. Provides pharmaceutical formulation expertise and commercial development perspective.
• Institute of Physical Chemistry, Romanian AcademyminorStrategic or Co-development Partner · 1 January 2022Academic partner in NANOTHER project for nanotheranostic development and other research collaborations.
• ICGEB Trieste, Italy (Computational Biology group)coreStrategic or Co-development Partner · 1 January 2021CRP/ROU21-01 project collaboration investigating brain-gut axis linking inflammatory bowel disease with anxiety and depression. ICGEB provides computational biology expertise and training for next generation scientists.
• EU-ROS Consortium (COST Action BM1203)coreStrategic or Co-development Partner · 1 January 2021European Network on Oxidative Stress and Redox Biology Research. IVB participates in network activities for advancing redox biology research and training.
• BenBedPhar (COST Action CA20121)coreStrategic or Co-development Partner · 1 January 2021Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Prof. Antonio Cuadrado chairs, Dr. Gina Manda serves as Vice-chair. IVB is grant holder. Focus on NRF2 drug development for chronic diseases.
• ELI-NP (Extreme Light Infrastructure - Nuclear Physics)coreStrategic or Co-development Partner · 1 January 2020Pan-European research infrastructure in Romania. IVB collaborates on biological systems under irradiation research using ultra-high power lasers and gamma-ray beams. Multiple joint projects including 13-ELI and ELI-09 for astrobiology and FLASH radiotherapy research.
• Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH)coreStrategic or Co-development Partner · 1 January 2016Long-standing collaboration in radiobiology research, particularly for ELI-NP projects. IFIN-HH provides physics and nuclear engineering expertise while IVB provides biomedical research capabilities. Partner in projects 13-ELI, ELI-09, and multiple radiation biology initiatives.
• University of Bucharest, Faculty of BiologycoreStrategic or Co-development Partner · 1 January 2016Academic partner in multiple research projects including ELI-RO initiatives. Provides biology expertise and student training for collaborative research programs.
• GSI Helmholtz Centre for Heavy Ion Research, GermanycoreStrategic or Co-development Partner · 1 January 2016International collaboration through AO-2017-IBER ESA program for investigating biological effects of radiation using GSI accelerator facility. Focus on redox signaling and NRF2 transcription factor research for space radiation protection.
• Autonomous University of Madrid, Spain (Prof. Antonio Cuadrado)coreStrategic or Co-development Partner · 1 January 2016Long-standing collaboration in NRF2 transcription factor research and redox biology. Prof. Cuadrado coordinates REDBRAIN project (P_37_732) for neurodegenerative disease research. Joint publications and project development in pharmacological NRF2 modulation.
• Lisbon University, Portugal (Prof. Luis Filipe Vieira Ferreira)coreStrategic or Co-development Partner · 1 January 2016M-ERA.NET NANOTHER project collaboration (2016-2019) for developing porphyrin-based theranostic compounds for cancer photodynamic therapy. Joint research in photochemistry and nanomedicine.
• Carol Davila University of Medicine and Pharmacy, RomaniacoreStrategic or Co-development Partner · 1 January 2016Collaborates in PORPHYDERM project for photodynamic therapy development and other biomedical research initiatives. Joint work on porphyrin synthesis and clinical applications.
• European Space Agency (ESA)coreStrategic or Co-development Partner · 1 January 2016AO-2017-IBER program collaboration for investigating biological effects of radiation relevant to spaceflight environment. Focus on astronaut radiation protection and space environment health consequences research.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Helmholtz Centre for Infection Research (HZI): German government-funded research centre conducting infectious disease, immunology, and redox biology research; comparable scale, public funding model, and translational research orientation to IVB.
• Pasteur Institute: Mission-aligned non-profit biomedical research foundation conducting fundamental and translational research in infectious disease, immunology, and cancer, with international scientific networks comparable to IVB's structure.
• INSERM: French national public research institute dedicated to human health and biomedical research; comparable in scope, public funding structure, and emphasis on translational and clinical research partnerships.
• Francis Crick Institute: Publicly funded biomedical discovery institute conducting cancer, neurodegeneration, and infection biology research at scale; serves as a comparable model for an integrated national research institute with international collaboration networks.
• ICGEB Trieste: International research organization in Trieste with active CRP/ROU21-01 collaboration with IVB on computational biology and systems biomedical research; comparable in intergovernmental funding model and biomedical research scope.
• Max Delbrück Center for Molecular Medicine (MDC): Government-funded biomedical research institute focused on molecular medicine, cancer, and cardiovascular disease, with translational programs analogous to IVB's biomedical research portfolio.
• Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH): Romanian national R&D institute and ELI-NP host; long-standing strategic partner on ELI radiobiology projects (13-ELI, ELI-09) and complementary physics/nuclear-engineering expertise to IVB's biomedical capabilities.

Emerging players

• Photocure ASA: Commercial-stage company developing porphyrin-based photodynamic therapy products for dermatology and oncology; directly comparable to IVB's porphyrin PDT and theranostic research direction and represents a potential commercialization counterpart.

Regional players

• Carol Davila University of Medicine and Pharmacy: Romanian medical university and active PORPHYDERM collaboration partner; comparable regional footprint in pathology and biomedical training and shares patient-referral and education channels with IVB.

Broad incumbents

• Eurofins Scientific: Global commercial laboratory services group with extensive pathology, genomics, and biomedical testing capabilities; comparable end-customer use cases in clinical diagnostics and preclinical research services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/incdvb.ro
• LinkedInlinkedin.com/company/victor-babes-national-institute-of-pathology

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute of Pathology Victor Babeş – Bucharest